Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Ariadne (drug)

From Wikipedia, the free encyclopedia
(Redirected from4C-D)
Psychoactive phenethylamine drug

Pharmaceutical compound
Ariadne
Clinical data
Trade namesDimoxamine (tentative)
Other namesARIADNE; 4-Methyl-2,5-dimethoxy-α-ethylphenethylamine; 2,5-Dimethoxy-4-methyl-α-ethylphenethylamine; 4C-D; 4C-DOM; "Four-carbon DOM"; α-Et-2C-D; α-Ethyl-2C-D; BL-3912; BL3912; Dimoxamine
Routes of
administration
Oral[1][2]
Drug classSerotonin5-HT2A,5-HT2B, and5-HT2C receptoragonist; Non-hallucinogenicserotonin5-HT2A receptoragonist;Antidepressant;Stimulant
ATC code
  • None
Legal status
Legal status
Identifiers
  • 1-(2,5-dimethoxy-4-methylphenyl)butan-2-amine
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC13H21NO2
Molar mass223.316 g·mol−1
3D model (JSmol)
  • O(c1cc(c(OC)cc1C[C@H](N)CC)C)C
  • InChI=1S/C13H21NO2/c1-5-11(14)7-10-8-12(15-3)9(2)6-13(10)16-4/h6,8,11H,5,7,14H2,1-4H3 checkY
  • Key:MLYCFWZIAJAIGW-UHFFFAOYSA-N checkY
  (verify)

Ariadne, also known chemically as4C-D or4C-DOM, by its developmental code nameBL-3912, and by its former tentative brand nameDimoxamine, is apsychoactive drug of thephenethylamine,phenylisobutylamine (α-ethylphenethylamine), and4C families.[3][1][2][4] It is ananalogue of thepsychedelic drugs2C-D andDOM, with 2C-D having no substitution at theα carbon, DOM having an α-methyl group, and Ariadne having an α-ethyl group.[3][1][2][4] Ariadne is takenorally.[1][2]

The drug is aserotonin5-HT2 receptorpartial agonist, including of the serotonin5-HT2A receptor, similarly to psychedelics.[3] However, Ariadne is nothallucinogenic in humans, but is stillpsychoactive, producingantidepressant and mildstimulant effects such as feelings ofwell-being andmental alertness.[3][1][2][5] The drug showsdopaminergic actions in animals, such asincreased motivation andreversal of parkinsonism, which may be mediated by serotonin 5-HT2A receptor activation-induceddopamine release in the brain.[3][1] It is thought that the non-psychedelic nature of Ariadne with retained psychoactive effects is due to reduced but still highefficacy at the serotonin 5-HT2A receptor relative to psychedelics.[3]

Ariadne was firstsynthesized byAlexander Shulgin in 1968 and its psychoactive effects were discovered by Shulgin in 1969.[5][3][1] It was developed as a potentialpharmaceutical drug atBristol Laboratories, for instance as an antidepressant and for various other uses, and enteredclinical trials around 1974.[5][3][4][2] The drug reachedphase 3 trials prior to its development being shelved.[5] The development of Ariadne is said to have been discontinued for strategic economic reasons rather than due to issues witheffectiveness orsafety.[5][3] There has been renewed interest in Ariadne and similar drugs in the 2020s owing to increased interest in psychedelics for treatment ofpsychiatric disorders.[3] Ariadne is not an explicitlycontrolled substance in theUnited States.[2]

Use and effects

[edit]

In his 1991 bookPiHKAL,Alexander Shulgin reported human tests of Ariadne at doses of up to 32 mgorally, finding that it produced "the alert of a psychedelic, with none of the rest of the package".[1] Very little published data exists about the human pharmacology of Ariadne apart from Shulgin's limited testing; unpublished human trials reportedly observed somepsychoactive effects, but nohallucinations.[6][3]

In his 2011 bookThe Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, Shulgin described (R)-Ariadne as increasingmental alertness and producing feelings ofwell-being at doses of 25 to 50 mg orally.[2] It was claimed to improve symptoms ofmanic depression inpsychotic individuals at doses of 50 to 100 mg orally and to improve symptoms ofParkinson's disease at a dosage of 100 mg/day orally.[2][3] Doses of up to 300 mg resulted in analtered state of consciousness but still no psychedelic effects.[3][2] For comparison, DOM shows psychoactive sub-hallucinogenic effects at doses of 1 to 3 mg orally and psychedelic effects at doses of more than 3 mg orally.[3]

Overdose

[edit]

Ariadne, as the (R)-enantiomer, is active at doses as low as 25 mg and was tested inclinical trials at doses of 50 to 100 mg.[3] Doses as high as 300 mg have been assessed, more than 10 times higher than the minimum reported active dose.[3] No psychedelic effects occurred at this or lower doses, but therapeutic effects were observed.[3]

Interactions

[edit]
See also:Psychedelic drug § Interactions, andTrip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]
Ariadne activities
TargetAffinity (Ki, nM)
5-HT1A>10,000 (Ki)
656 (EC50Tooltip half-maximal effective concentration)
68% (EmaxTooltip maximal efficacy)
5-HT1B>10,000 (Ki)
4,023 (EC50)
90% (
Emax)
5-HT1DND (Ki)
612 (
EC50)
65% (
Emax)
5-HT1END (Ki)
727 (
EC50)
79% (
Emax)
5-HT1FND (Ki)
690 (
EC50)
75% (
Emax)
5-HT2A120 (Ki)
39–1,300 (EC50)
80–91% (
Emax)
5-HT2B>10,000 (Ki)
217–>32,000 (EC50)
68–85% (
Emax)
5-HT2CND (Ki)
120–582 (
EC50)
34–93% (
Emax)
5-HT3>10,000
5-HT4ND (Ki)
ND (EC50)
<20% (
Emax)
5-HT5AND (Ki)
ND (EC50)
<20% (
Emax)
5-HT6ND (Ki)
1,038 (
EC50)
42% (
Emax)
5-HT7ND (Ki)
ND (EC50)
<20% (
Emax)
α1A>10,000
α1B,α1DND
α2A>10,000
α2B,α2CND
β1,β2>10,000
β3ND
D1,D2>10,000
D3D5ND
H1,H2>10,000
H3,H4ND
M1M3>10,000
M4,M5ND
I1ND
σ1,σ2ND
TAAR1Tooltip Trace amine-associated receptor 1ND
SERTTooltip Serotonin transporter>10,000 (Ki)
>50,000 (IC50Tooltip half-maximal inhibitory concentration)
ND (EC50)
NETTooltip Norepinephrine transporter>10,000 (Ki)
ND (IC50)
ND (EC50)
DATTooltip Dopamine transporter>10,000 (Ki)
>100,000 (IC50)
ND (EC50)
MAO-ATooltip Monoamine oxidase A>10,000 (Ki)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified.Refs:[7][3][8]

Ariadne is apotent andselectiveagonist of theserotonin5-HT2 receptors, including of the serotonin5-HT2A,5-HT2B, and5-HT2C receptors.[3][8] However, it is lessefficacious in activating the serotonin 5-HT2A receptor, including theGq, G11, andβ-arrestin2 signaling pathways, compared to the related drugDOM, and this weakerpartial agonism may be responsible for its lack of psychedelic effects.[3][8] In addition to the serotonin 5-HT2 receptors, Ariadne is a lower-affinity agonist of the serotonin5-HT1 receptors.[3] Ariadne shows essentially no activity at themonoamine transporters.[3]

Ariadne shows a markedly attenuatedhead-twitch response, a behavioral proxy of psychedelic effects, in animals, although it does still significantly induce a weak head-twitch response.[3][8][9] The drug substitutes for DOM in rodentdrug discrimination tests, albeit with dramatically lowerpotency thanDOx drugs like DOM itself,DOET, andDOB.[9] It has also been shown to produce stimulus generalization in rats trained to respond toLSD[6] andMDMA.[10] Ariadne's capacity to fully substitute for MDMA is not shared with DOM and is unusual among psychedelics, but is shared withα-ethyltryptamine (αET).[10][11] In monkeys, Ariadne was found to possiblyincrease motivation, as it caused monkeys that had stopped running mazes to begin running them again.[1] Ariadne has also been found to be effective in ananimal model ofParkinson's disease, where it reversedmotor deficits similarly tolevodopa.[3]

Serotonin 5-HT2A receptor agonists have been found to increasedopamine levels in thenucleus accumbens and othermesolimbic areas.[3] Non-hallucinogenic serotonin 5-HT2A receptor agonists like Ariadne may produce this effect without causing psychedelic effects.[3] This action may underlie the preliminary observations of effectiveness of Ariadne in the treatment ofparkinsonism in animals and humans.[3]

Chemistry

[edit]

Ariadne, also known as 4-methyl-2,5-dimethoxy-α-ethylphenethylamine, is asubstituted phenethylamine andamphetaminederivative.[1][2] It is theanalogue of2,5-dimethoxy-4-methylamphetamine (DOM) in which theα-methylgroup has been replaced with an α-ethyl group and is the analogue of2,5-dimethoxy-4-methylphenethylamine (2C-D) with an ethyl group substituted at the α carbon.[3][1][2]

Synthesis

[edit]

Thechemical synthesis of Ariadne has been described.[1][2]

Analogues

[edit]

Other related compounds include the4C derivatives4C-B (the α-ethyl homologue of2C-B andDOB) and4C-T-2 (the α-ethyl homologue of2C-T-2 andAleph-2) among others.[1][12][3] Unlike Ariadne, 4C-B has been reported to produce pronounced psychedelic effects, although generally milder than those of 2C-B or DOB.[12]

History

[edit]

Ariadne was firstsynthesized byAlexander Shulgin in 1968 and he discovered itspsychoactive effects in 1969.[5][3][1] Shulgin reported that the drug was tested byBristol Laboratories as anantidepressant, in an anecdote where he was explaining how human testing is invaluable (compared to animal testing) on drugs that change the state of the mind. He said, "Before they launched into a full multi-clinic study to determine whether it's going to be worth the animal studies or not, every person on the board of directors took it."[4] InThe Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds (2011), he described it also being evaluated for increasingmental alertness ingeriatric individuals, treatingParkinson's disease, and treatingpsychosis andmanic depression.[2][3] The tentative commercial name of Ariadne wasDimoxamine.[2] (R)-Ariadne was said to have completedphase 2clinical trials and to have reachedphase 3 trials, but the actual clinical data were never disclosed and further development was halted due to strategic economic reasons.[5][3] However, according to journalistHamilton Morris, the United StatesCentral Intelligence Agency (CIA) may have had involvement in the discontinuation of Ariadne's development.[13]

Society and culture

[edit]

Names

[edit]

Ariadne's alternative name4C-DOM or4C-D stands for "four-carbon DOM", whereas the name of 2C-D stands for "two-carbon DOM".[3] Another name of Ariadne isα-Et-2C-D, which stands for α-ethyl-2C-D.[9]Racemic Ariadne is additionally known by the former developmental code nameBL-3912, while the (R)-enantiomer of Ariadne (R)-Ariadne, is known by the former developmental code nameBL-3912A.[3][2]

Legal status

[edit]

United States

[edit]

Ariadne is not an explicitlycontrolled substance anywhere in theUnited States as of 2011.[2]

See also

[edit]

References

[edit]
  1. ^abcdefghijklmnAlexander T. Shulgin,Ann Shulgin (1991)."#8 ARIADNE; 4C-DOM; BL-3912; DIMOXAMINE; 1-(2,5- DIMETHOXY-4-METHYLPHENYL)-2-AMINOBUTANE; 2,5- DIMETHOXY-a-ETHYL-4-METHYLPHENETHYLAMINE".PiHKAL: A Chemical Love Story (1st ed.). Berkeley, CA: Transform Press. pp. 475–480.ISBN 978-0-9630096-0-9.OCLC 25627628.
  2. ^abcdefghijklmnopqrShulgin A, Manning T, Daley PF (2011)."#7. ARIADNE".The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley, CA: Transform Press. pp. 7–9.ISBN 978-0-9630096-3-0.OCLC 709667010.It was developed commercially by the Bristol-Myers Company to increase mental alertness in geriatric patients, and was patented in Germany, France, and the United States (Shulgin, 1974a, 1974b, 1977a). Its commercial name, Dimoxamine, does not have a classic female ring to it. [...] In normal human subjects, R-4C-DOM orally at 25—50 mg increased mental alertness and feelings of well-being. At 100 mg/day, the symptoms of Parkinson's disease went into remission. With psychotic patients there was a consistent relief of manic depression at doses of 50-100 mg (Shulgin, 1977a; Partyka et al., 1978). A single human oral ingestion of 270 mg produced a change of state of consciousness but evoked no psychedelic effects (Winter, 1980).
  3. ^abcdefghijklmnopqrstuvwxyzaaabacadaeafagahCunningham MJ, Bock HA, Serrano IC, Bechand B, Vidyadhara DJ, Bonniwell EM, et al. (January 2023)."Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs".ACS Chemical Neuroscience.14 (1):119–135.doi:10.1021/acschemneuro.2c00597.PMC 10147382.PMID 36521179.
  4. ^abcdShulgin A (2021).The Nature of Drugs. Berkeley, California: Transform Press. pp. 299–300.ISBN 978-0-9995472-1-2.
  5. ^abcdefgShulgin AT (1987)."The "Social-Chemistry" of Pharmacological Discovery: Interview with Dr. Alexander T. Shulgin. January 26, 1986".Social Pharmacology.1 (3):279–290.
  6. ^abWinter JC (1980-05-01). "Effects of the phenethylamine derivatives, BL-3912, fenfluramine, and Sch-12679, in rats trained with LSD as a discriminative stimulus".Psychopharmacology.68 (2):159–162.doi:10.1007/BF00432134.PMID 6776559.S2CID 12221170.
  7. ^Sharp T, Ippolito A (May 2025)."Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists".Br J Pharmacol.doi:10.1111/bph.70050.PMID 40405723.
  8. ^abcdWallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, et al. (December 2023)."Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential".Nat Commun.14 (1): 8221.doi:10.1038/s41467-023-44016-1.PMC 10724237.PMID 38102107.
  9. ^abcHalberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD (May 2020)."Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species".Neuropharmacology.167 107933.doi:10.1016/j.neuropharm.2019.107933.PMC 9191653.PMID 31917152.
  10. ^abGlennon RA (October 1993). "MDMA-like stimulus effects of alpha-ethyltryptamine and the alpha-ethyl homolog of DOM".Pharmacology, Biochemistry, and Behavior.46 (2):459–462.doi:10.1016/0091-3057(93)90379-8.PMID 7903460.S2CID 54356633.
  11. ^Oberlender RA (May 1989)."Stereoselective aspects of hallucinogenic drug action and drug discrimination studies of entactogens".Purdue e-Pubs. Purdue University.The results of initial studies (Nichols et al., 1986) generally demonstrated the lack of LSD-Iike discriminative stimulus properties for the members of the entactogen drug class. This was confirmed and extended to other hallucinogens in tests with rats trained on entactogens. These results are summarized in Table 12. Table 12. Results of DD tests comparing entactogens and hallucinogens. [...] It seems clear that entactogen activity is distinct from that of hallucinogens. [...]
  12. ^abTrachsel D, Lehmann D, Enzensperger C (2013).Phenethylamine: Von der Struktur zur Funktion. Nachtschatten Verlag AG. p. 832.ISBN 978-3-03788-700-4.Das α-Ethylhomologon von 2C-B (6) trägt den Namen (303; auch 4C-B) und wurde von Rausch eingehender untersucht [140, 145]. Es vermochte eine ausgeprägte psychedelische Wirkung mit Bewusstseinsvertiefung, Euphorie und Sensationen besonders im Bereich des Tastsinns hervorzurufen (50—80mg, rund acht Stunden Wirkdauer). Visuelle Pseudohalluzinationen traten kaum auf. Das Iodoanalogon DOI-B (304) wurde nur bis zu einer Dosierung von 4mg geprüft und zeigte dabei keinerlei Wirkungen [8].
  13. ^Smith S (25 September 2025)."The Hidden Side of Psychedelic Research ft. Hamilton Morris".YouTube.Vice News. Retrieved29 September 2025.

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Stimulants
Depressants
Hallucinogens
Entactogens
Psychiatric drugs
Others
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ariadne_(drug)&oldid=1323690334"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp